Ovarian cancer is the deadly gynecological cancer, and is the seventh most common cancer in women globally. Most of the women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.
The major driving forces are rising ovarian cancer incidence, a growing number of clinical trials for innovations, increasing health expenditure, use of combination therapies for the treatment of ovarian cancer, increasing geriatric population.
The rising ovarian cancer incidence is expected to boost the market. For instance, according to the World Cancer Research Fund International (WCRF), ovarian cancer is the seventh most common cancer in women globally and causes more deaths per year than any other gynecological cancer. In 2016, around 235,200 new cases and 140,000 deaths were reported worldwide. The National Cancer Institute (NCI) estimates that 22,350 women will be diagnosed with ovarian cancer in 2019, and 13,980 will die. Thus, the growing ovarian cancer incidence is driving the market.
The presence of healthy ovarian cancer product pipeline is expected to boost the market. For instance,
The high cost of cancer treatment is likely to hamper the market. For instance, according to a study published online on November 7, 2017, in Obstetrics & Gynecology, women with ovarian cancer who had both surgery and adjuvant chemotherapy, the average medical expenditures are about $100,000 in the first year after surgery.
Based on the type, the global ovarian cancer market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, stromal cell ovarian cancer, and small cell ovarian cancer.
Based on the treatment type, the global ovarian cancer market is segmented into targeted therapy, surgery, chemotherapy, immunotherapy, and others.Targeted therapy is expected to grow at a high rate over the forecast period, owing to the presence of approved targeted therapy drugs.
Based on diagnosis type, the global ovarian cancer market is segmented into blood tests, imaging tests, laparoscopy, colonoscopy, and others.
Blood tests segment is expected to boost the market over the forecast period, owing to the presence of ongoing research and development activities. For instance, in February 2019, researchers from the University of Kansas (KU) in Lawrence and the KU Cancer Center and KU Medical Center in Kansas City have developed an ultrasensitive cancer-detecting device, called a "3-D-nanopatterned microfluidic chip,. This could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.
Based on drug class, the global ovarian cancer market is segmented into PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors.PARP Inhibitors segment is expected to boost the market over the forecast period. This is owing to the presence of approved PARP inhibitors and ongoing research activities.
Geographically, the global ovarian cancer market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is dominating the global ovarian cancer market in 2018 and is estimated to hold significant market size over the forecast period (2019-2026) owing to the increasing incidence of ovarian cancer, and presence of ongoing research activities.
Increasing incidence of ovarian cancer is expected to boost market growth over the forecast period. For instance, according to the National Cancer Institute, there were over 22,000 new cases of ovarian cancer in the US in 2018. Also, more than 14,000 of these resulted in death. Thus, the growing incidence of ovarian cancer is driving the market.
The key players operating in the global ovarian cancer market are Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the ovarian cancer market globally. For instance,
On September 4, 2019, IMV, and Wistar Institute partnered to develop T-cell immunotherapy against cancers with BRAF mutations. Under the partnership, IMV would use its proprietary DPX drug delivery platform to design immunotherapy using small molecules provided by the Winstar Institute.
On August 7, 2019, Personalis, Inc. stated that the University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care would use the company's cancer immunogenomics platform, named ImmunoID NeXT, for the investigation of biomarkers of response to a novel treatment in women with ovarian cancer.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including: